Showing 1 - 7 results of 7 for search 'John J. Tentler', query time: 0.03s Refine Results
  1. 1
    Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

    Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Can... by Anastasia A. Ionkina, John J. Tentler, Jihye Kim, Anna Capasso, Todd M. Pitts, Karen A. Ryall, Rebekah R. Howison, Peter Kabos, Carol A. Sartorius, Aik Choon Tan, S. Gail Eckhardt, Jennifer R. Diamond

    Published 2017-05-01
    Get full text
    Article
  2. 2
    Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

    Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer by Todd M. Pitts, Dennis M. Simmons, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, John J. Tentler, Diana Cittelly, D. Ryan Ormond, Wells A. Messersmith, S. Gail Eckhardt, Jennifer R. Diamond

    Published 2020-03-01
    Get full text
    Article
  3. 3
    Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models

    Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models by S. Lindsey eDavis, S. Lindsey eDavis, Kelli M. Robertson, Todd M. Pitts, Todd M. Pitts, John J. Tentler, John J. Tentler, Erica L. Bradshaw-Pierce, Erica L. Bradshaw-Pierce, Erica L. Bradshaw-Pierce, Peter J. Klauck, Stacey M. Bagby, Stephanie L. Hyatt, Heather M. Selby, Anna eSpreafico, Jeffrey A Ecsedy, John J. Arcaroli, John J. Arcaroli, Wells A. Messersmith, Wells A. Messersmith, Aik Choon eTan, Aik Choon eTan, S. Gail eEckhardt, S. Gail eEckhardt

    Published 2015-06-01
    Get full text
    Article
  4. 4
    RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

    RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer by John J. Tentler, Julie Lang, Anna Capasso, Deog Joong Kim, Ely Benaim, Young B. Lee, Andrew Eisen, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, Todd M. Pitts, Roberta Pelanda, S. Gail Eckhardt, Jennifer R. Diamond

    Published 2020-11-01
    Get full text
    Article
  5. 5
    Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

    Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. by Todd M Pitts, Timothy P Newton, Erica L Bradshaw-Pierce, Rebecca Addison, John J Arcaroli, Peter J Klauck, Stacey M Bagby, Stephanie L Hyatt, Alicia Purkey, John J Tentler, Aik Choon Tan, Wells A Messersmith, S Gail Eckhardt, Stephen Leong

    Published 2014-01-01
    Get full text
    Article
  6. 6
    A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

    A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer by Jennifer R. Diamond, S. G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara Aisner, Daniel L. Gustafson, Anna Capasso, Sharon Sams, Peter Kabos, Kathryn Zolman, Tiffany Colvin, Anthony D. Elias, Anna M. Storniolo, Bryan P. Schneider, Dexiang Gao, John J. Tentler, Virginia F. Borges, Kathy D. Miller

    Published 2018-08-01
    Get full text
    Article
  7. 7
    Association of the Epithelial-to-Mesenchymal Transition (EMT) Phenotype with Responsiveness to the p21-Activated Kinase Inhibitor, PF-3758309, in Colon Cancer Models

    Association of the Epithelial-to-Mesenchymal Transition (EMT) Phenotype with Responsiveness to the p21-Activated Kinase Inhibitor, PF-3758309, in Colon Cancer Models by Todd M Pitts, Gillian N Kulikowski, Aik-Choon eTan, Brion William Murray, John J Arcaroli, John J Tentler, Anna eSpreafico, Heather M Selby, Maria I Kachaeva, Kelly L McPhillips, Blair C Britt, Erica Lynn Bradshaw-Pierce, Erica Lynn Bradshaw-Pierce, Wells A Messersmith, Marileila eVarella-Garcia, S. Gail eEckhardt

    Published 2013-03-01
    Get full text
    Article

Search Tools: